Research memoRegeneron Pharmaceuticals, Inc. (REGN) · NASDAQMemo of October 16, 2026

Regeneron dividend: cash coverage and yield

Regeneron pays a $0.94 quarterly dividend, or $3.76 annualized. Its $3,765.2 million of free cash flow covered the $370.3 million paid in 2025.

3.41
Dividend paid per share, 2025
0.5%
Dividend yield
3.4%
Real free cash flow yield
4.6%
Free cash flow yield
Read the full Regeneron memoYour first report is free · no card
Every number traced to Regeneron's filings8 chapters · 16,925 words235 sources cited

How much does Regeneron pay in dividends?

Dividends rise cautiously in the base case from $4.00 to $4.24 and $4.52 per share. The bear holds them at $3.76, the current annualized rate from a $0.94 quarterly dividend. The bull reaches $4.24, $4.72 and $5.20. Free cash flow was $3,765.2 million and net cash was $5,288.0 million, supporting increases, but the dividend has only a short history.

The company increasingly returned cash to owners. Shareholder payouts rose from $1,645.4 million in 2021 to $3,808.9 million in 2025. Regeneron began regular quarterly dividends in February 2025 and paid $370.3 million that year; buybacks used another $3,438.6 million. A buyback purchases shares, reducing the number of shares that divide future earnings. That can help each remaining share, but only if Regeneron does not overpay.

Dividend per share against free cash flow per share (US$ per share)0.0052.8320210.0023.5520220.0024.4720230.0022.2120243.4125.522025Dividends paid, per shareReal free cash flow per share
The forecast's tablebase case, then bear / bull in brackets; USD millions, per share in USD, unless shown
October 2027October 2028October 2029
Earnings6,400 (5,400 / 7,000)7,100 (5,000 / 8,000)7,700 (4,600 / 9,200)
Shares (millions)100 (102 / 99.80)98.30 (101 / 97.00)96.30 (99.70 / 94.40)
Dividends per share4.00 (3.76 / 4.24)4.24 (3.76 / 4.72)4.52 (3.76 / 5.20)

Is Regeneron’s dividend covered by its cash?

Free cash flow subtracts investment in productive assets from operating cash. On the broader definition used here, $1,213.7 million of capital spending left $3,765.2 million of free cash flow. Regeneron’s own measure was $4,080.5 million because it excluded purchased intangible rights. Those rights included the $155.0 million voucher and $160.3 million of Libtayo contingent consideration.

Follow the money: where the free cash flow wentUS$ millions
20252024202320222021
Free cash flow3,765.23,538.93,667.63,398.06,529.4
− Dividends paid370.30000
− Share buybacks3,438.62,603.32,235.02,082.81,645.4
= Free cash flow not paid out935.61,432.61,315.24,884.0
Paid to shareholders3,808.92,603.32,235.02,082.81,645.4
Paid out, % of free cash flow101.2%73.6%60.9%61.3%25.2%

What is Regeneron’s dividend yield at its share price?

At $788.48 and 19.5x trailing earnings, the price implies about $40.43 per share. A forward P/E of 12.6x implies about $62.58 per share. If the definitions match, investors are assuming roughly 55% earnings growth, even though the forward number has not yet been earned.

What an investor pays todayUS$ millions
Today (Oct 16, 2026)
Share price788.48
P/E, last 12 months (calculated)19.5x
Dividend yield (calculated)0.5%

What this means. Enterprise value is lower than market value because the company has more cash and short-term investments than debt, making the business effectively cheaper after using that cash.

From the full memo · 1. The business

Regeneron Pharmaceuticals invents, makes and sells specialist medicines. Its business is easiest to understand by following a treatment from laboratory to patient, then following the dollar through partners, payers and costs.

Continue reading, free
Your first report is free · no card

Where these numbers come from

More on Regeneron

Regeneron stock forecastRegeneron earnings

Its rivals

AbbVie (ABBV)Amgen (AMGN)Lilly (LLY)

Browse

All stocksS&P 500 companiesCompanies R
The full Regeneron memoYour first report is free
Read it